Chronic Kidney Disease

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study.

Patients’ smoking behaviors may be associated with elevated risks for chronic kidney disease, but more data are needed, according to researchers.

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, CVD and overall mortality.

Registered dietitian nutritionists caring for patients with chronic kidney disease are frequently challenged to help address multiple chronic diseases, comorbidities and acute issues to achieve goals for health and well-being.

Obesity is an important health issue for patients with chronic kidney disease, speeding its progression, contributing to disability and limiting access to organ transplantation. Up to now, nephrologists typically do not manage obesity.

For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.

Healio has compiled a list of the most-read nephrology articles in 2024.

Healio has compiled a list of the most-read nephrology news stories related to diabetes and metabolic dysfunction in 2024.

Healio has compiled a list of the most-read nephrology news stories related to chronic kidney disease in 2024.

Healio has compiled a list of the most-read nephrology-related exclusive features in 2024.